Advanced search
Publication Cover
Clinical Toxicology Volume 54, 2016 - Issue 3
Submit an article Journal homepage
733
Views
8
CrossRef citations to date
0
Altmetric
Brief Communication

Dabigatran deliberate overdose: two cases and suggestions for laboratory monitoring

Ioana VladEmergency Department, Sir Charles Gairdner Hospital, Perth, Australia; Correspondence[email protected]
,
Jason ArmstrongEmergency Department, Sir Charles Gairdner Hospital, Perth, Australia;
,
James RidgleyIntensive Care Unit, Joondalup Hospital, Perth, Australia
&
Ovidiu PascuEmergency Department, Sir Charles Gairdner Hospital, Perth, Australia;
Pages 286-289 | Received 11 Aug 2015, Accepted 25 Nov 2015, Published online: 06 Jan 2016

References

  • Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation. 2011;123:1436–1450.
  • van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116–1127.
  • Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.
  • Dager WE, Gosselin RC, Kitchen S, et al Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study. Ann Pharmacother. 2012;46:1627–1636.
  • Okubo K, Kuwahara T, Takagi K, et al. Relation between dabigatran concentration, as assessed using the direct thrombin inhibitor assay, and activated clotting time/activated partial thromboplastin time in patients with atrial fibrillation. Am J Cardiol. 2015;115:1696–1699.
  • Chiew AL, Khamoudes D, Chan BS. Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose. Clin Toxicol (Phila). 2014;52:283–287.
  • Baglin T, Keeling D, Kitchen S. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. Br J Haematol. 2012;159:427–429.
  • Woo JS, Kapadia N, Phanco SE, et al Positive outcome after intentional overdose of dabigatran. J Med Toxicol. 2013;9:192–195.
  • Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis. 2012;23:138–143.
  • Simpson SE. Pharmacobezoars described and demystified. Clin Toxicol (Phila). 2011;49:72–89.
  • Ganetsky M, Babu KM, Salhanick SD, et al. Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol. 2011;7:281–287.
  • Chang DN, Dager WE, Chin AW. Removal of dabigatran by hemodialysis. Am J Kidney Dis. 2013;61:487–489.
  • Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511–520.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.